BeOne Medicines (SHSE:688235) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688235 BeOne Medicines Ltd SHSE:688235
76 GF Score
Price ¥267.62
GF Value ¥340.54
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BeOne Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ¥2,050 Mil. BeOne Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ¥11,857 Mil. BeOne Medicines's annualized EBITDA for the quarter that ended in Jun. 2026 was ¥10,693 Mil. BeOne Medicines's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 1.30.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BeOne Medicines's Debt-to-EBITDA or its related term are showing as below:

SHSE:688235' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.18   Med: -0.35   Max: 1.77
Current: 0.97

During the past 13 years, the highest Debt-to-EBITDA Ratio of BeOne Medicines was 1.77. The lowest was -3.18. And the median was -0.35.

SHSE:688235's Debt-to-EBITDA is ranked better than
55.92% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs SHSE:688235: 0.97

BeOne Medicines  (SHSE:688235) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

BeOne Medicines Debt-to-EBITDA Related Terms

BeOne Medicines Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Debt-to-EBITDA Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BeOne Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

SHSE:688235 vs RVMD, MRNA, ALNY: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, BeOne Medicines's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeOne Medicines Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Debt-to-EBITDA falls into.


SHSE:688235
76GF Score
BeOne Medicines Ltd SHSE:688235
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BeOne Medicines's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(941.33874575 + 13033.56362425) / 4433.6478650044
=3.15

BeOne Medicines's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2050.0525458 + 11856.7943892) / 10692.814554829
=1.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is BeOne Medicines (SHSE:688235) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of ¥267.62 is trading 21.4% below its estimated GF Value™ of ¥340.54. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for SHSE:688235:

  • Debt-to-EBITDA:
  • GF Value™: ¥340.54 vs. price of ¥267.62 (21.4% below fair value)
  • GF Score™: 76/100 with 5 warning signs

No single metric tells the full story. See the SHSE:688235 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
76GF Score

Get the complete analysis for SHSE:688235

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥267.62
Price
¥340.54
GF Value